ArticleThe Pan African medical journal2025
Use of anticoagulants in children: a cross-sectional study at Albert Royer Children Hospital and Cardio-Pediatric Surgery Center of Fann University Hospital in Dakar, Senegal.
Article in The Pan African medical journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: the use of anticoagulants in children is less frequent and requires more precautions (higher doses, unsuitable formulations, risk of treatment-related complications). We aimed to describe the challenge of using anticoagulants in children in a sub-Saharan hospital. Methods: we conducted a cross-sectional study at the Albert Royer National Children's Center and the Cardio-Pediatric Surgery Center of Fann University Hospital, with a prospective recruitment over a 6-month period. All patients aged 0 to 15 years who had received anticoagulant treatment and biological monitoring were included. Results: thirty-one patients were included. The mean age was 13 years (extremes: 13 days and 15 years) with 58.1% of girls (N=18). Among the causes of thrombotic events requiring anticoagulation, cardiac diseases were the most common in 80.6% (N=25), followed by tumor, autoimmune and traumatic causes at equal proportions of 3% (N=1). Treatment was preventive in 61.2% (N=19) of cases and curative in 38.8% (N=12). The most commonly used anticoagulant was vitamin K antagonist (VKA) in 70.9% of cases (N=22); followed by low molecular weight heparin (LMWH) in 61.29% (N=19); then unfractionated heparin (UFH) in 45.1% (N=14). One patient received rivaroxaban. All patients who received LMWH were treated with 200 IU/kg/day. The median dose of UFH was 8.3 IU/kg/h. For patients receiving VKA; 52.9% (N=9) had a dosage less than 0.1mg/kg/day. In 63.2% (N=12) of cases, the switch molecule was VKA. The median time to achieve the target INR was 13.5 days. Complications occurred in 9 patients (29.03%): heparin-induced thrombocytopenia (N=2), vitamin K antagonist overdose (N=6) and epistaxis (N=1). Conclusion: this study shows, on the one hand, that children are mostly under-dosed with anticoagulants; on the other hand, when the effective dose is reached, nearly one-third of anticoagulation-related accidents occur in this population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.